Advisory Committee Review Will Test Whether One Trial Will Do The Trick For Bristol's Ipilimumab

Panelists may want to wait for results from a second Phase III trial and, given severe side effects, are likely to want a robust risk management plan.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet